echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Food Articles > Genomic editing technology cannot be safely used in humans, scientists stress

    Genomic editing technology cannot be safely used in humans, scientists stress

    • Last Update: 2021-03-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Science and Technology Daily (reporter
    ) According to the U.S. "Science" magazine website recently reported that a multi-national scientific research organizations of the international
    conference published a report on the 3rd, genetic human genome editing (HHGE) is not yet safe and effective for human standards, countries should decide whether to approve such technologies into clinical applications, should be widely discussed and strictly monitored.
    International
    , called Human Reproduction Genome Editing Clinical Applications International
    , is made up of 18 representatives from 10 national research institutions, including the National School of Medicine, the National
    and the Royal Society.
    the report says that once the genome of a human embryo is edited, it should not be used for fertility unless there is definitive evidence that precisely changing the genome can lead to reliable results and does not lead to unexpected changes. At present, no genome editing technology, including CRISPR technology, can meet this standard.
    is the insertion, deletion, or replacement of DNA (deoxybonucleic acid) fragments in a particular gene. In theory, genome editing can alter specific genetic characteristics, thus not only modifying embryonic genes, eliminating genetic diseases, but also enhancing physiological characteristics, but this "design baby" involves ethical and technical issues - the main danger of editing human embryos is that there will be unexpected "off-target effects" and these DNA changes cannot be detected between the embryo and the mother.
    the report classified the potential uses of HHGE and created a level 6 structure based on the risk situation. If a country decides to approve the application of HHGE technology, the report says, such technology should also be limited to the prevention of severe single-gene genetic diseases at an early stage, and should only be considered if there is no other option. In addition, the report provides basic guidance on HHGE technology regulation at the national and international levels., co-chair of theAssociation, said: "More research is needed to verify the effectiveness of genome editing techniques in human embryos to ensure that they can be accurately modified without off-target effects. In
    addition, the report calls for the establishment of an international "scientific advisory group" to assess the proposed use of HHGE, to provide regular updates on relevant technologies, and to assess what would happen if edited embryos were implanted into the mother. It also recommends the establishment of an international mechanism where clinicians or researchers can report on their plans or use of HHGE.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.